Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport
- PMID: 13679362
- DOI: 10.1074/jbc.M309026200
Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport
Abstract
Current biochemical characterizations of cystic fibrosis (CF) sputum do not address the high degree of microheterogeneity in the rheological properties of the mucosal matrix and only provide bulk-average particle diffusion coefficients. The viscoelasticity of CF sputum greatly reduces the diffusion rates of colloidal particles, limiting the effectiveness of gene delivery to underlying lung cells. We determine diffusion coefficients of hundreds of individual amine-modified and carboxylated polystyrene particles (diameter 100-500 nm) embedded in human CF sputum with 5 nm and 33 ms of spatiotemporal resolution. High resolution multiple particle tracking is used to calculate the effective viscoelastic properties of CF sputum at the micron scale, which we relate to its macroscopic viscoelasticity. CF sputum microviscosity, as probed by 100- and 200-nm particles, is an order of magnitude lower than its macroviscosity, suggesting that nanoparticles dispersed in CF sputum are transported primarily through lower viscosity pores within a highly elastic matrix. Multiple particle tracking provides a non-destructive, highly sensitive method to quantify the high heterogeneity of the mucus pore network. The mean diffusion coefficient becomes dominated by relatively few but fast-moving particles as particle size is reduced from 500 to 100 nm. Neutrally charged particles with a diameter <200 nm undergo more rapid transport in CF sputum than charged particles. Treatment with recombinant human DNase (Pulmozyme) reduces macroviscoelastic properties of CF sputum by up to 50% and dramatically narrows the distribution of individual particle diffusion rates but surprisingly does not significantly alter the ensemble-average particle diffusion rate.
Similar articles
-
Cystic fibrosis sputum: a barrier to the transport of nanospheres.Am J Respir Crit Care Med. 2000 Nov;162(5):1905-11. doi: 10.1164/ajrccm.162.5.9909009. Am J Respir Crit Care Med. 2000. PMID: 11069833
-
Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.Pulm Pharmacol Ther. 2007;20(6):708-17. doi: 10.1016/j.pupt.2006.08.008. Epub 2006 Sep 9. Pulm Pharmacol Ther. 2007. PMID: 17055310
-
Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.Eur J Pharm Biopharm. 2018 Mar;124:125-137. doi: 10.1016/j.ejpb.2017.12.017. Epub 2017 Dec 29. Eur J Pharm Biopharm. 2018. PMID: 29291931
-
Mucus, phlegm, and sputum in cystic fibrosis.Respir Care. 2009 Jun;54(6):726-32; discussion 732. doi: 10.4187/002013209790983269. Respir Care. 2009. PMID: 19467160 Review.
-
Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery.Adv Drug Deliv Rev. 2018 Jan 15;124:64-81. doi: 10.1016/j.addr.2017.12.002. Epub 2017 Dec 12. Adv Drug Deliv Rev. 2018. PMID: 29246855 Free PMC article. Review.
Cited by
-
Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases.Int J Mol Sci. 2024 Feb 5;25(3):1933. doi: 10.3390/ijms25031933. Int J Mol Sci. 2024. PMID: 38339210 Free PMC article. Review.
-
Advances in the Evaluation of Gastrointestinal Absorption Considering the Mucus Layer.Pharmaceutics. 2023 Nov 30;15(12):2714. doi: 10.3390/pharmaceutics15122714. Pharmaceutics. 2023. PMID: 38140055 Free PMC article. Review.
-
In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates.Heliyon. 2023 Nov 25;9(12):e22821. doi: 10.1016/j.heliyon.2023.e22821. eCollection 2023 Dec. Heliyon. 2023. PMID: 38125473 Free PMC article.
-
Nanoparticle-Mediated Strategies for Enhanced Drug Penetration and Retention in the Airway Mucosa.Pharmaceutics. 2023 Oct 13;15(10):2457. doi: 10.3390/pharmaceutics15102457. Pharmaceutics. 2023. PMID: 37896217 Free PMC article. Review.
-
Engineering in vitro models of cystic fibrosis lung disease using neutrophil extracellular trap inspired biomaterials.J Mater Chem B. 2023 Oct 11;11(39):9419-9430. doi: 10.1039/d3tb01489d. J Mater Chem B. 2023. PMID: 37701932
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
